Subcutaneous on par with intravenous delivery of daratumumab in multiple myeloma
13 Dec 2019
bởiTristan Manalac
Subcutaneous (SC) daratumumab (DARA) showed comparable performance to intravenous (IV) admission in patients with relapsed or refractory multiple myeloma (RRMM), according to a phase III, randomized, open-label, active-controlled multicentre study presented at the recently concluded 61st Annual Meeting and Exposition of the American Society of Haematology (ASH 2019).